M. S. Smyth

发表

Barry A. Bunin, R. Borchardt, C. Crews, 2005 .

Preparation of fluoro- and hydroxy-4-(phosphonomethyl)-D,L-phenylalanine suitably protected for solid-phase synthesis of peptides containing hydrolytically stable analogs of O-phosphotyrosine

T. Burke, A. Otaka, M. Nomizu, 1993 .

Enantioselective synthesis of N-boc and N-fmoc protected diethyl 4-phosphono(difluoromethyl)-L-phenylalanine; agents suitable for the solid-phase synthesis of peptides containing nonhydrolyzable analogues of O-phosphotyrosine

T. Burke, M. S. Smyth, 1994 .

The first asymmetric synthesis of a lycorine alkaloid. Total synthesis of (+)-1-deoxylycorine

M. S. Smyth, A. Schultz, M. Holoboski, 1993 .

Synthesis of 4-phosphono(difluoromethyl)-D,L-phenylalanine and N-boc and N-Fmoc derivatives suitably protected for solid-phase synthesis of nonhydrolyzable phosphotyrosyl peptide analogues

P. Roller, A. Otaka, T. Burke, 1993 .

A general method for the preparation of benzylic α,α-difluorophosphonic acids; non-hydrolyzable mimemtics of phosphotyrosine

T. Burke, M. S. Smyth, H. Ford, 1992 .

Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase-resistant SH2 domain inhibitors.

S. Shoelson, P. Roller, T. Burke, 1994, Biochemistry.

Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.

J. Wikel, J. Morin, J. Mccowan, 1997, Journal of medicinal chemistry.

Hydroxylated 2-(5'-salicyl)naphthalenes as protein-tyrosine kinase inhibitors.

T. Burke, I. Horak, M. S. Smyth, 1993, Journal of medicinal chemistry.

The First Asymmetric Synthesis of a Lycorine Alkaloid. Total Synthesis of (+)‐1‐Deoxylycorine.

M. S. Smyth, A. Schultz, M. Holoboski, 2010 .

THE FIRST ASYMMETRIC TOTAL SYNTHESES OF (+)-LYCORINE AND (+)-1-DEOXYLYCORINE

M. S. Smyth, A. Schultz, M. Holoboski, 1996 .

Why is phosphonodifluoromethyl phenylalanine a more potent inhibitory moiety than phosphonomethyl phenylalanine toward protein-tyrosine phosphatases?

L. Wu, P. Roller, J. den Hertog, 1995, Biochemical and biophysical research communications.

Non-amine based analogues of lavendustin A as protein-tyrosine kinase inhibitors.

A. Levitzki, T. Burke, N. Osherov, 1993, Journal of medicinal chemistry.

The total synthesis of piptosidin

M. S. Smyth, A. J. Poss, 1987 .

The Total Synthesis of Piptosidin (I).

M. S. Smyth, A. J. Poss, 1988 .

The total synthesis of L-talonic lactone

M. S. Smyth, A. J. Poss, 1989 .

The Total Synthesis of L-Talonic Lactone (II).

M. S. Smyth, A. J. Poss, 1990 .

The total synthesis of D-mycinose

M. S. Smyth, A. J. Poss, 1988 .

Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 3: synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes.

A. Pandey, G. Park, T. Schotten, 2002, Bioorganic & medicinal chemistry letters.

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

S. Demo, M. Aujay, M. Bennett, 2007, Cancer research.

Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitors.

J. Mccowan, J. A. Jakubowski, K. Ruterbories, 1997, Journal of medicinal chemistry.

Spirocyclic nonpeptide glycoprotein IIb–IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undec-9-yl template

Julie A. Heath, A. Pandey, Theo Schotten, 2001 .

Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 1: design of potent and specific 3,9-diazaspiro[5.5]undecanes.

A. Pandey, T. Schotten, R. Scarborough, 2001, Bioorganic & medicinal chemistry letters.

ENANTIOSELECTIVE SYNTHESIS OF N-Boc AND N-Fmoc PROTECTED DIETHYL 4-PHOSPHONO(DIFLUOROMETHYL)-L-PHENYLALANINE (F2Pmp)

T. Burke, M. S. Smyth, 1996 .

Cyclic peptide inhibitors of phosphatidylinositol 3-kinase p85 SH2 domain binding.

S. Shoelson, P. Roller, T. Burke, 1994, Biochemical and biophysical research communications.

Synthesis and structure activity studies of phosphatase resistant SH2 domain inhibiting peptides: D-amino acid effects

S. Shoelson, P. Roller, T. Burke, 1995 .

Synthesis and structure-activity studies of SH2 binding peptides containing hydrolytically stable analogs of O -phosphotyrosine

S. Shoelson, P. Roller, T. Burke, 1994 .

Enantioselective Synthesis of N‐Boc and N‐Fmoc Protected Diethyl 4‐ Phosphono(difluoromethyl)‐L‐phenylalanine (F2Pmp).

M. S. Smyth, Burket. R. Jun. Burket. R. Jun., 1996 .

Norleucine as a replacement for methionine in phosphatase-resistant linear and cyclic peptides which bind to p85 SH2 domains

S. Shoelson, P. Roller, T. Burke, 1994 .

Characterization of neutralizing antibodies to bovine enterovirus elicited by synthetic peptides

F. Brown, S. Martin, E. Hoey, 2005, Archives of Virology.

Chemically synthesized peptides elicit neutralizing antibody to bovine enterovirus.

F. Brown, S. Martin, E. Hoey, 1990, The Journal of general virology.

Diethyl 3-Bromopropene Phosphonate an Alkylative 8-Keto Phosphonate Equivalent

M. S. Smyth, A. J. Poss, 1987 .

Phosphonate inhibitors of protein-tyrosine and serine/threonine phosphatases.

T. Burke, H. Kole, T. Burke, 1995, The Biochemical journal.

Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.

A. Pandey, G. Park, S. Hollenbach, 2004, Journal of medicinal chemistry.

Deprotection and cleavage methods for protected peptide resins containing 4-[(diethylphosphono)difluoromethyl]-D,L-phenylalanine residues

P. Roller, T. Burke, A. Otaka, 1993 .